Saturday 17 October 2026
Export CGEM’s income statement to Excel — free account
Cullinan Therapeutics, Inc.
CGEM Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.
12.93
1.07
−7.64%
Follow CGEM
Cullinan Therapeutics, Inc. (CGEM) P/E ratio
Cullinan Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 9.9× (June 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 9.9×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.6× |
| MGTX MeiraGTx Holdings PLC compare | 12.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)